Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation—a matched pair analysis-Reference-Cited by-同舟云学术

Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation—a matched pair analysis

Published:2013-03-05 Issue:7 Volume:92 Page:945-952
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Busemann Christoph,Neumann Thomas,Schulze Meike,Klenner Anne,Thiele Thomas,Greinacher Andreas,Dölken Gottfried,Krüger William H.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-013-1714-4.pdf

Reference25 articles.

1. Bacigalupo A (2005) Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 35(3):225–231

2. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855–864

3. Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T et al (2008) Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 36(8):1047–1054

4. Hale G (2002) Alemtuzumab in stem cell transplantation. Med Oncol 19(Suppl):S33–S47

5. Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN et al (2011) Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. Br J Haematol 153(2):244–252

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients;Canadian Journal of Infectious Diseases and Medical Microbiology;2020-10-10

2. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation;Transplant Infectious Disease;2017-12-27

3. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation;Brazilian Journal of Medical and Biological Research;2017

4. Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant;Experimental and Clinical Transplantation;2016-02

5. Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation;Journal of Cancer Research and Clinical Oncology;2016-01-16